Zentalis Pharmaceuticals, Inc.
ZNTL$232M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO166 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 1, 2026
41wMarket Overview
Stock performance and key metrics
ZNTL News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
ZN-d5
Amyloidosis
Niraparib
Ovarian Cancer
azenosertib
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
ZN-c3
Uterine Serous Carcinoma
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
ZN-d5 | Phase 2 | Amyloidosis | - |
Niraparib | Phase 2 | Ovarian Cancer | - |
azenosertib | Phase 2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | - |
ZN-c3 | Phase 2 | Uterine Serous Carcinoma | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply